Financial Daily from THE HINDU group of publications
Saturday, Mar 13, 2004

Cross Currency

Group Sites

Corporate - Announcements
Marketing - New Products & Services

Ranbaxy launches drug for erectile dysfunction

Our Bureau

New Delhi , March 12

RANBAXY Laboratories Ltd has launched Forzest (Tadalafil), its most recently approved prescription medicine for the treatment of erectile dysfunction (ED) in men.

Currently, oral specific medication for management of erectile dysfunction, Sildenafil, is available. This is valued at Rs 70 crore. However, in the case of Sildenafil, the pill has to be taken one hour before the indulgence. But Forzest has an advantage over Sildenafil in terms of longer therapeutic window as it acts faster and more importantly can be taken any time up to 36 hours in advance. Given these advantages, Tadalafil gives "freedom of choice" and has been called as the weekend pill.

Erectile dysfunction is a seriously under-diagnosed condition, which largely goes untreated due to embarrassment of patients. It is estimated that about 150 million people suffer from it and about nine out of every 10 men do not seek treatment.

In India, it is estimated that about 50 million patients suffer from the disorder. Studies also indicate that men with diabetes have three-fold higher incidence and 50 per cent of them develop the condition within 10 years of being diagnosed with diabetes.

Mr Sanjeev I. Dani, Regional Director, India operations, Ranbaxy, said, "Introduction of Forzest will provide Indian doctors with best-in-class and contemporary therapeutic option for management of erectile dysfunction, which also gives greater time window to the patients".

More Stories on : Announcements | New Products & Services | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Hind Sanitaryware to invest Rs 195 cr in glass division

`Indal can use coal block only for proposed project'
GMR Energy receives Rs 100-cr investment
Ranbaxy launches drug for erectile dysfunction
Shree Syn board meet
GE Capital to invest in Ashok Leyland Finance
Patent cases againt Dr Reddy's, Ranbaxy — `Pfizer's victory not to impact Indian generics'
ICRA grading to BE Billimoria
Highest safety rating for PowerGrid bonds
Work apace on Oswal ammonia plant in Australia
CPCL plant to produce water from sewage
`Cheap Chinese imports hurting domestic tyre cos' — MRF looks to raise exports to 50 pc of sales
IOC aims for presence from `drilling to dispensing'
Bharat Forge rights issue placed at 1:20
Sterlite files draft offer for rights issue
Decks cleared for TRL revival
Ester Ind rehabilitation moves a step ahead
Coking coal shortage hits SAIL plants
Hindustan Latex Director

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line